In the long-running debate on the general counsel’s role in a company’s compliance program (often covered in these pages), the government recently weighed in. As part of the new corporate integrity agreement the federal government entered into with Johnson & Johnson in November, the pharma giant is required to maintain a chief compliance officer independent of the general counsel’s office.
The 101-page agreement was part of the $2.2 billion settlement with the U.S. Department of Justice to resolve civil and criminal allegations related to the off-label marketing for children, the elderly and the mentally disabled of the antipsychotic drug Risperdal. J&J declined to comment.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
